|
2. Etiologie
|
|
|
|
2.8 Etiologie - Contraceptifs, THS
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
Does Cancer Screening Save More Lives Overall? Not Necessarily [WBUR]
|
|
|
|
|
|
We
know cancer remains a terrifying and stigmatized illness. But public
health campaigns should be more realistic, more humble. We want people
to see information like the graphics designed by the Harding Center for
Risk Literacy, which display absolute risks and benefits rather than
misleading, but commonly used, “relative risk” statistics.
|
|
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
It's Time to End Mammograms, Some Experts Say [TIME]
|
|
|
|
|
|
Autier
says he is not against screening for cancer, but says that based on his
findings, mammography is likely not the ideal way to detect breast
cancer. In contrast, he says, screening for cervical cancer and colon
cancer are extremely effective; those methods have been linked to a 70%
to 80% drop in deaths from those cancers.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Roche Tecentriq combo effective, but is it enough? [Pharmafile]
|
|
|
|
|
|
Key
information on the co-primary endpoint of overall survival is yet to be
revealed but the company teased that the data is “encouraging”. Whether
Roche can take a serious portion of the market away from Keytruda and
BMS’ Opdivo in lung cancer could depend on the data.
|
|
|
|
|
|
|
|
|
Merck raises stakes in lung cancer as rivals close in [Reuters]
|
|
|
|
|
|
Some
industry experts expect Merck to release initial survival results as
early as mid-2018. That could allow the company to expand use of the
drug more quickly to patients without PDL1 in their tumors, and build a
stronger case for European approval.
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.6 ESMO
|
|
|
|
|
|
5.7 SABCS
|
|
|
|
|
|
5.7.2 SABCS-divers
|
|
|
|
5.7.3 SABCS-AACR
|
|
|
|
|
|
Postmenopausal Women Who Lose Weight May Have Reduced Breast Cancer Risk [AACR]
|
|
|
|
|
|
Chlebowski
and colleagues analyzed data from the Women’s Health Initiative (WHI)
Observational Study. This program tracks the health of postmenopausal
women between the ages of 50 and 79. Participants who had a normal
mammogram, no prior breast cancer, and were not underweight (BMI ≥ 18.5)
were eligible for enrollment in Chlebowski’s study.
|
|
|
|
|
|
|
|
5.7.4 SABCS-essais
|
|
|
|
|
|
|
|
5.7.5 SABCS-biopsies liquides
|
|
|
|
|
5.8.1 ASH - Communiqués
|
|
|
|
5.8.3 ASH - Divers
|
|
|
|
5.8.4 ASH - CAR T
|
|
|
|
|
|
|
|
|
|
A Milestone for CAR T Cells [NEJM]
|
|
|
|
|
|
CAR-engineered
T cells are a revolutionary treatment for patients with advanced blood
cancers. Unfortunately, CAR-engineered T cells have been largely
ineffective in patients with metastatic solid cancers, which account for
the majority of cancer-related deaths.
|
|
|
|
|
|
|
|
5.8.6 ASH - Leucémies
|
|
|
|
5.8.7 ASH - Lymphomes
|
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
U.S. House committee 'may reconsider' WHO cancer agency funds [Reuters]
|
|
|
|
|
|
In
a letter to the France-based International Agency for Research on
Cancer (IARC) - a semi-autonomous unit of the WHO - the U.S. House of
Representatives Science, Space, and Technology (SST) Committee warned it
“may reconsider U.S. taxpayer funding” if IARC “does not demonstrate
transparency”.
|
|
|
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|